1429027-74-6

Basic information

• Product Name: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene
• Synonyms: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene
• CAS NO: 1429027-74-6
• Molecular Weight: 331.132
• Mol File: 1429027-74-6.mol

Chemical Properties

• CAS DataBase Reference: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene(1429027-74-6)
• EPA Substance Registry System: 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene(1429027-74-6)

Safety Data

• Hazardous Substances Data: 1429027-74-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its chemical structure allows for the creation of a wide range of derivatives that can be tailored for specific medicinal applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene is employed as a starting material for the production of pesticides and other agrochemicals. Its reactivity and structural features make it a valuable component in the formulation of effective crop protection products.
Used in Organic Synthesis:
As a reagent in organic synthesis, 2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene is used to facilitate a variety of chemical reactions, including nucleophilic substitutions. This property is crucial for the preparation of complex organic molecules and the advancement of synthetic chemistry.
Used in Materials Science:
2-(benzyloxy)-1-bromo-4-(trifluoromethyl)benzene is used as a component in the development of advanced materials with unique properties. Its incorporation into material compositions can lead to the creation of new materials with enhanced characteristics, such as improved stability, reactivity, or selectivity, which are valuable in various applications across different industries.

Upstream product

• 402-07-3 1-bromo-2-methoxy-4-(trifluoromethyl)benzene 
• 100-39-0 benzyl bromide 
• 402-05-1 2-bromo-5-(trifluoromethyl)phenol 

Relevant articles and documents

Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach

Covalent ligands are of great interest as therapeutic drugs or biochemical tools. Here, we reported the discovery of highly selective and irreversible inhibitors of lipoprotein-associated phospholipase A2 (Lp-PLA2) using a covalent fragment-based approach. The crystal structure of Lp-PLA2 in complex with a covalent fragment not only reveals the covalent reaction mechanism but also provides a good starting point to design compound 8, which has a more than 130,000-fold and 3900-fold increase in potency and selectivity, respectively, compared to those of the covalent fragment. Furthermore, fluorescent probes with high selectivity and sensitivity are developed to characterize Lp-PLA2 and its enzymatic activity in vitro or even in living cells in a way more convenient than immunoblotting tests or immunofluorescence imaging. Overall, we provide a paradigm for application of the covalent fragment-based strategy in covalent ligand discovery and the advantage of enol-cyclocarbamate as a new warhead in designing covalent inhibitors of serine hydrolases.

MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2

The present application provides a compound of Formula: or a pharmaceutically acceptable salt thereof, wherein ring B, L1, ring A, L2, n, R1, R2, R3, R4, and X1 are as described herein. Pharmaceutical compositions comprising the compound, as well as the methods of making and using the compound, are also provided.

Oxazolidinone compound as well as preparation method, application and pharmaceutical composition thereof

The invention relates to an oxazolidinone compound used as an Lp-PLA2 covalent inhibitor and a pharmaceutical composition of the oxazolidinone compound, the structure of the oxazolidinone compound isshown as a general formula I, and R1, R2 and R3 are defined as the specification and claims. The compound shown in the general formula I or the stereoisomer or the pharmaceutically acceptable salt thereof can be used as the Lp-PLA2 covalent inhibitor to prevent and/or treat and/or improve diseases related to Lp-PLA2 enzyme activity. Meanwhile, the stereoisomer or the pharmaceutically acceptable salt of the compound shown in the general formula I can be used as an Lp-PLA2 specific molecular probe.

NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.

DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS

The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.